Nick Leeper, MD

Nick Leeper, MD is Professor, Chief of Vascular Medicine, and Director of Vascular Research at Stanford University. A board-certified cardiologist, Dr. Leeper specializes in the care of patients with atherosclerotic cardiovascular diseases. He is actively engaged with the Society for Vascular Medicine (SVM), the Gordon Research Conferences (GRC), and the American Society for Clinical Investigation (ASCI), and has held multiple volunteer roles with the American Heart Association (AHA). Dr. Leeper leads a translational research program that leverages human genetics and advanced immunology to discover and develop new cardiovascular therapeutics. Dr. Leeper is also an accomplished biotech founder. He previously co-founded Forty Seven, Inc., an immuno-oncology company acquired by Gilead Sciences for approximately $4.9 billion. He is additionally a co-founder and Board Director of Bitterroot Bio, a cardio-immunology biotechnology company that launched out of stealth with a $145 million Series A financing co-led by ARCH Venture Partners (with Deerfield Management). Dr. Leeper earned a BA in Chemistry and an MD from the University of Chicago. He completed internal medicine training at UCSF before fellowships in cardiovascular disease and vascular medicine at Stanford University.